Delving into the Latest Updates on PM-1016 with Synapse

[Translation] A Phase I clinical trial to evaluate the tolerability, safety and preliminary efficacy of oncolytic adenovirus PM1016 encoding TNF-α and IL-2 in subjects with advanced malignant solid tumors and a Phase IIa clinical trial to investigate preliminary efficacy in subjects with advanced malignant solid tumors

I期：评估 PM1016 治疗晚期恶性实体瘤受试者中的安全性和耐受性；确定 PM1016 的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。 IIa期剂量扩展研究：初步研究PM1016 单药在拟定的晚期恶性实体瘤受试者中的抗肿瘤客观缓解率。

[Translation]

Phase I: Evaluate the safety and tolerability of PM1016 in subjects with advanced malignant solid tumors; determine the maximum tolerated dose (MTD) and/or recommended dose (RP2D) of PM1016. Phase IIa dose expansion study: Preliminary study of the objective response rate of PM1016 monotherapy in subjects with advanced malignant solid tumors.

Start Date23 Jun 2021

Sponsor / Collaborator

GenIbet Biopharmaceuticals SA

[+2]

100 Clinical Results associated with PM-1016

Login to view more data

100 Translational Medicine associated with PM-1016

Login to view more data

100 Patents (Medical) associated with PM-1016

Login to view more data

100 Deals associated with PM-1016

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	CN	GenIbet Biopharmaceuticals SA	23 Jun 2021
Advanced Malignant Solid Neoplasm	Phase 2	CN	TILT Biotherapeutics Oy	23 Jun 2021
Advanced Malignant Solid Neoplasm	Phase 2	CN	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	23 Jun 2021
Hepatocellular Carcinoma	IND Approval	CN	TILT Biotherapeutics Oy	18 Aug 2022